TEXAS — The U.S. Department of Energy approved the Documented Safety Analysis for Oklo's Groves Isotope Test Reactor in Texas. This approval confirms the reactor's hazard evaluations, operating requirements, and safety controls.

Following this approval, the Groves Isotope Test Reactor will proceed to the final pre-startup review phase. Oklo stated that construction milestones for the reactor in Texas remain on track, and the company is targeting first criticality for the Groves Isotope Test Reactor in July 2026.

Oklo clarified the next steps in the regulatory process. "The remaining steps are DOE's readiness review and startup approval," the company stated.

Oklo's management observed that new regulatory developments with the U.S. Nuclear Regulatory Commission could potentially reduce approval timelines to under 18 months. The company noted that the Part 57 pathway may become usable later in 2026. Oklo maintains a partnership with the Idaho National Laboratory.

Oklo reported a loss of $0.07 per share for the quarter that concluded in March 2025. This loss increased to $0.19 per share for the quarter ending March 2026. Wall Street analysts forecast approximately $1.16 million in revenue for Oklo for the year 2026.

As of July 6, 2026, Oklo stock trades near $52 per share. The stock has a 52-week range of $44.80 to $193.84 and was down 28% year-to-date on that date. However, Oklo stock rose almost 4% during the five days preceding July 6, 2026, with a 12-month average price target of $84.10. Oklo also possesses a fuel recycling technology.